<DOC>
	<DOCNO>NCT00170937</DOCNO>
	<brief_summary>The metabolic syndrome classification patient constellation risk factor may include abdominal obesity , hypertension , elevate blood lipid sugar . Three factor together constitute metabolic syndrome place patient great risk development diabetes cardiovascular disease . The purpose study determine whether two common drug low blood pressure , whether use separately combination , different effect blood sugar level patient diagnose metabolic syndrome .</brief_summary>
	<brief_title>A 16 Week Study Evaluate Effect Insulin Sensitivity Valsartan ( 320 mg ) Hydrochlorothiazide ( 25 mg ) Combined Alone , Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prehypertension</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Waist circumference : male &gt; 40 '' , females &gt; 35 `` MSSBP ≥ 130 mmHg ≤ 160 mmHg MSDBP ≥ 85 mmHg ≤ 100 mmHg At least one follow criterion : Fasting plasma glucose 5.9 6.9 mmol/L ; Serum triglycerides &gt; 150 mg/dL ; LDL Cholesterol : &lt; 40 mg/dL male ; &lt; 50 mg/dL female MSSBP &gt; 180 mmHg MSDBP &gt; 110 mmHg Inability discontinue prior antihypertensive period 4 week . History diabetes History stroke , transient ischemic attack myocardial infarction . Significant weight change &gt; 10 lbs screen period Patients take diuretic 3 month prior screen . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>METABOLIC SYNDROME , VALSARTAN , HYDROCHLOROTHIAZIDE , HYPERTENSION ,</keyword>
</DOC>